Nelipepimut-S, an advanced peptide-based immunotherapeutic intervention, has demonstrated significant efficacy within the biomedical sector as it pertains to breast cancer management. Acting with precision, it selectively engages HER2-positive malignancies, thereby amplifying and fortifying the immune system's retaliation against these deleterious cells.
CAT No: R2072
CAS No: 160212-35-1
Synonyms/Alias: NELIPEPIMUT-S;Neuvax;160212-35-1;NeuVax vaccine;KIFGSLAFL;Nelipepimut-S [USAN];E75 peptide;UNII-7M0A29CD8B;7M0A29CD8B;DTXSID80166835;L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L-phenylalanyl-;(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid;Nelipepimut-S (USAN);L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L-phenylalanyl-L-leucine;Human receptor tyrosine-protein kinase erbB-2 (proto-oncogene Neu, tyrosine kinase- type cell surface receptor HER2, CD340)-(347-355)-peptide;Nelipepimut s;E75 HER2 peptide;E-75 PEPTIDE;10: PN: WO2015050181 SEQID: 10 claimed protein;CHEMBL386200;NELIPEPIMUT S [WHO-DD];DTXCID3089326;AHOKKYCUWBLDST-QYULHYBRSA-N;CHEBI:230310;Her2 369-377;BDBM50409332;AKOS040753235;DA-76075;E-75;HER-2/NEU PEPTIDE (369-377);HY-106204;CS-0025241;Q27268544;HUMAN RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (PROTO-ONCOGENE NEU, TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2, CD340)-(347-355)-PEPTIDE;
Chemical Name: (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C50H78N10O11 |
M.W/Mr. | 995.2 |
Sequence | One Letter Code:KIFGSLAFL Three Letter Code:H-Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu-OH |
InChI | InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1 |
InChI Key | AHOKKYCUWBLDST-QYULHYBRSA-N |
Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCCCN)N |
Isomeric SMILES | CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com